Ras G J, Anderson R, Eftychis H A, Koch U, Theron A, Van Wyk H A, Olivier L R
S Afr Med J. 1984;66(25):955-8.
Twenty-six patients aged between 27 and 71 years with chronic bronchitis were divided into a control group of 6 and two groups of 10 patients each who received either erythromycin stearate or amoxycillin 1500 mg/d for 2 weeks and 1000 mg/d for 12 weeks thereafter. Immunological function tests were performed before starting chemotherapy and thereafter at 2 weeks and 14 weeks. Clinical evaluations and lung function tests showed no significant changes in any of the groups during the study period. In the control group no changes in cellular and humoral immune functions were noted. In the group receiving amoxycillin decreased responses of lymphocytes to the mitogen phytohaemagglutinin were observed after 14 days. In the erythromycin-treated group, increased polymorphonuclear leucocyte (PMNL) motility and mitogen-induced transformation were observed at 14 days but these increases were not statistically significant. In this group the markedly depressed PMNL migration found in 3 individuals before treatment improved considerably. These results indicate that chemotherapy and chemoprophylaxis with either amoxycillin or erythromycin stearate do not compromise the host immunodefences.
26例年龄在27至71岁之间的慢性支气管炎患者被分为一个6人的对照组和两个各有10名患者的组，后两组患者分别接受硬脂酸红霉素或阿莫西林治疗，治疗方案为：前2周每天1500毫克，之后12周每天1000毫克。在开始化疗前、化疗2周后和14周后进行免疫功能测试。临床评估和肺功能测试显示，在研究期间，任何一组均无显著变化。对照组的细胞免疫和体液免疫功能未见变化。在接受阿莫西林治疗的组中，14天后观察到淋巴细胞对有丝分裂原植物血凝素的反应降低。在红霉素治疗组中，14天时观察到多形核白细胞（PMNL）活力增加和有丝分裂原诱导的转化，但这些增加无统计学意义。在该组中，治疗前3名患者中发现的明显降低的PMNL迁移有了相当大的改善。这些结果表明，用阿莫西林或硬脂酸红霉素进行化疗和化学预防不会损害宿主的免疫防御能力。
